References
- Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415–1421.
- Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995;64:621–651.
- Leaman DW, Leung S, Li X, Stark GR. Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J 1996;10:1578–1588.
- Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 1995;13:369–398.
- Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630–1635.
- Ramana CV, Grammatikakis N, Chernov M, et al Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J 2000;19:263–272.
- Shang Y, Kakinuma S, Amasaki Y, et al Aberrant activation of interleukin-9 receptor and downstream Stat3/5 in primary T-cell lymphomas in vivo in susceptible B6 and resistant C3H mice. In Vivo 2008;22:713–720.
- Momose S, Tamaru J, Kishi H, et al Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion. Hum Pathol 2009;40:75–82.
- Levy DE, Gilliland DG. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 2000;19:2505–2510.
- Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA 1996;93:7673–7678.
- Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002;109:1139–1142.
- Catlett-Falcone R, Landowski TH, Oshiro MM, et al Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105–115.
- Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343–3356.
- Koca E, Haznedaroglu IC. Imatinib mesylate and the management of chronic myeloid leukemia (CML). Turk J Hematol 2005;22:161–172.
- Peled A, Hardan I, Trakhtenbrot L, et al Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells 2002;20:259–266.
- Schindler T, Bornmann W, Pellicena P, et al Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938–1942.
- Baran Y, Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007;12:497–503.
- Frame D. New strategies in controlling drug resistance. J Manag Care Pharm 2007;13:13–17.
- Illmer T, Schaich M, Platzbecker U, et al P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004;18:401–408.
- Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004;279:34227–34239.
- Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996;183:811–820.
- Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997;159:4720–4728.
- Weber-Nordt RM, Egen C, Wehinger J, et al Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 1996;88:809–816.
- Garcia R, Yu CL, Hudnall A, et al Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997;8:1267–1276.
- Teglund S, McKay C, Schuetz E, et al Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998;93:841–850.